MSON
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CIN rates MSOS Daily Bear ETF Neutral, with two-out-of-five conviction and a composite score in the high-50s. The rating sits firmly within the Neutral band. Fundamentals provide the principal support, scoring in the low-80s on exceptional revenue-growth and gross-margin subscores, while operating profitability, market-cap tier, and cash-runway measures contribute less. Regulatory factors rank in the mid-50s, supported by jurisdiction posture and a clean enforcement record but constrained by weak filing cadence. Market evidence scores 40 because no quote is available, and editorial evidence ranks at 30 amid no newsroom or brief activity. The resulting setup combines strong reported commercial metrics with limited market confirmation and a stretched financial condition.
Licensed fundamentals data show year-over-year revenue growth of roughly 44% and a gross margin slightly above 71%, explaining the 93.5 growth subscore and perfect gross-margin subscore. Those strengths do not extend below gross profit: operating margin remains negative at approximately 12.5%, EBITDA is negative by about $5.7 million, and net income reflects a loss near $14.5 million. Market capitalization stands around $462 million, while the cash-burn ratio is approximately 1.2%, supporting only moderate market-cap and cash-runway contributions. Primary regulatory filings show no recorded filing date and no regulatory events across either the 90-day or 180-day periods. Institutional pricing feeds provide no current quote, while CIN newsroom coverage records no relevant newsroom or brief hits. Filing cadence, price discovery, and operating losses therefore cap conviction despite strong top-line expansion and gross economics.
The forward catalyst is a conversion of the dominant fundamentals pillar from gross-profit strength into improved operating performance. Continued revenue expansion at the current broad pace, paired with preservation of the gross margin above 70%, would create operating leverage and reinforce the strongest pillar without implying that stretched finances have normalized. Better filing cadence could improve regulatory support, but it remains secondary to the earnings structure. The single most important signal to watch is whether the negative operating margin begins narrowing while gross-margin strength holds.
- IR email
- info@advisorshares.com
- IR page
- Investor relations
- CEO
- Noah Hamman
- CFO
- Dan Ahrens
- SEC CIK
- 0000880432
- Website
- Company website
- Market cap
- $462.5M
- Enterprise value
- $478.5M
- Price to book
- 3.42
- Price to sales
- 6.25
- Revenue (TTM)
- $74.0M
- Gross profit (TTM)
- $52.6M
- EBITDA
- $-5.7M
- Operating margin
- -12.5%
- Profit margin
- -19.6%
- Rev growth YoY
- 43.5%
- Return on equity
- -10.3%
- Return on assets
- -2.9%
- EPS (TTM)
- $-0.84
- EPS est. current year
- $-0.95
- Wall St. target price
- $28.00
- Shares outstanding
- 17.4M
- Insider ownership
- 20.9%
- Institutional ownership
- 41.0%
- Beta
- 1.35
- Full-time employees
- 281
- GICS sector
- Healthcare
- GICS industry
- Medical Devices
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for MSON (MSON)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for MSON (MSON), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for MSON are maintained by Cannabis Investor News and refreshed throughout the trading day.